Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOA LIFT vs JUVÉDERM VOLIFT for Nasolabial Folds
NCT07794878Phase 3Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Aug 2026
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in nasolabial folds (2 arms), sponsored by AbbVie Inc. Primary endpoints: Percentage of Participants With Responder Status Based on Evaluating Investigator's Live Assessment of Nasolabial Fold Severity Scale (NLFSS) at 6 months and Number of Participants With Adverse Events at 13 months. Started Aug 2026; status: recruiting.
02
Conditions
nasolabial folds
Beyond the preview
Go deeper on NCT07794878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07794878.